Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
Clearmind Medicine (Nasdaq: CMND) has announced the publication of a patent by Mexico's National Patent Office (IMPI) for its combination therapy treatment. The patent covers an innovative treatment combining MEAI and N-Acylethanolamines, targeting various binge behaviors including alcohol, eating, tobacco, shopping, and sexual conduct.
The patent emerged from Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on developing treatments for central nervous system disorders. The partnership aims to research combination therapies that integrate psychedelic compounds with N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
Clearmind Medicine (Nasdaq: CMND) ha annunciato la pubblicazione di un brevetto da parte dell'Ufficio Nazionale dei Brevetti del Messico (IMPI) per il suo trattamento con terapia combinata. Il brevetto copre un trattamento innovativo che combina MEAI e N-Acilethanolamine, mirato a diverse comportamenti compulsivi tra cui alcol, alimentazione, tabacco, acquisti e comportamenti sessuali.
Il brevetto è emerso dalla collaborazione di Clearmind con SciSparc (Nasdaq: SPRC), focalizzandosi sullo sviluppo di trattamenti per disturbi del sistema nervoso centrale. La partnership mira a ricercare terapie combinate che integrino composti psichedelici con la famiglia delle N-Acilethanolamine, inclusa la Palmitoiletanolamide (PEA).
Clearmind Medicine (Nasdaq: CMND) ha anunciado la publicación de una patente por parte de la Oficina Nacional de Patentes de México (IMPI) para su tratamiento de terapia combinada. La patente cubre un tratamiento innovador que combina MEAI y N-Acilethanolaminas, dirigido a varios comportamientos compulsivos que incluyen alcohol, alimentación, tabaco, compras y conducta sexual.
La patente surgió de la colaboración de Clearmind con SciSparc (Nasdaq: SPRC), centrándose en el desarrollo de tratamientos para trastornos del sistema nervioso central. La asociación tiene como objetivo investigar terapias combinadas que integren compuestos psicodélicos con la familia de N-Acilethanolaminas, incluida la Palmitoiletanolamina (PEA).
클리어마인드 메디신 (Nasdaq: CMND)은 멕시코 국립특허청(IMPI)가 발표한 조합 요법 치료에 대한 특허를 공지했습니다. 이 특허는 MEAI와 N-아실에탄올아민을 결합한 혁신적인 치료법을 다루고 있으며, 알코올, 식사, 담배, 쇼핑, 성행위를 포함한 다양한 폭식 행동을 목표로 하고 있습니다.
이 특허는 클리어마인드가 사이스파크 (Nasdaq: SPRC)와 협력하는 과정에서 나왔다고 하며, 중추신경계 장애 치료 개발에 초점을 맞추고 있습니다. 이 파트너십은 N-아실에탄올아민 계열 성분과 함께 정신활성 물질을 결합한 조합 요법을 연구하는 것을 목표로 합니다. 여기에는 팔미토일에탄올아민(PEA)이 포함됩니다.
Clearmind Medicine (Nasdaq: CMND) a annoncé la publication d'un brevet par l'Office national des brevets du Mexique (IMPI) pour son traitement par thérapie combinée. Le brevet couvre un traitement innovant combinant MEAI et N-Acylethanolamines, visant divers comportements de frénésie, y compris l'alcool, la nourriture, le tabac, le shopping et la conduite sexuelle.
Le brevet a émergé de la collaboration de Clearmind avec SciSparc (Nasdaq: SPRC), axée sur le développement de traitements pour les troubles du système nerveux central. Le partenariat vise à rechercher des thérapies combinées intégrant des composés psychédéliques avec la famille des N-Acylethanolamines, y compris la Palmitoylethanolamide (PEA).
Clearmind Medicine (Nasdaq: CMND) hat die Veröffentlichung eines Patents durch das Nationale Patentamt von Mexiko (IMPI) für seine Kombinationstherapie angekündigt. Das Patent umfasst eine innovative Behandlung, die MEAI und N-Acylethanolamine kombiniert und auf verschiedene übermäßige Verhaltensweisen wie Alkohol, Essen, Tabak, Einkaufen und sexuelles Verhalten abzielt.
Das Patent entstand aus der Zusammenarbeit von Clearmind mit SciSparc (Nasdaq: SPRC), die sich auf die Entwicklung von Behandlungen für Störungen des zentralen Nervensystems konzentriert. Die Partnerschaft zielt darauf ab, Kombinationstherapien zu erforschen, die psychedelische Verbindungen mit der Familie der N-Acylethanolamine integrieren, einschließlich Palmitoylethanolamin (PEA).
- Patent publication in Mexico strengthens intellectual property portfolio
- Strategic collaboration with SciSparc expands treatment development capabilities
- None.
Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today a patent publication by the Instituto Mexicano de la Propriedad Industrial (IMPI), the National Mexico Patent Office. The patent refers to the Company’s innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
The patent is part of Clearmind’s successful collaboration with SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
About SciSparc Ltd.
SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the new patent Clearmind Medicine (CMND) received in Mexico?
What conditions does Clearmind's (CMND) new patented treatment target?
Who is Clearmind Medicine (CMND) collaborating with on this patent?
What compounds are included in Clearmind's (CMND) patented combination therapy?
